top of page
News, Events and Updates
Search
Apr 6, 2016
Anavex Annual Stockholders Meeting
Mar 14, 2016
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
Mar 14, 2016
AF710B, a Concomitant Activator of M1 Muscarinic and Sigma-1 Receptors: Possibly Disease-Modifying
Mar 10, 2016
Anavex Announces 2-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response
Feb 26, 2016
Assessment of ANAVEX 2-73 in a MECP2 Rett Syndrome Mouse Model
Feb 25, 2016
Anavex Presents Precinical Results of ANAVEX 2-73 in Rett Syndrome
Feb 17, 2016
ANAVEX 2-73 Preclinical Data in New Indication to be Presented at ACTRIMS 2016
Feb 11, 2016
Sigma-1 Receptor Agonists Inhibit Oligodendrocyte Cytotoxicity Induced by Molecules
Feb 8, 2016
Anavex Reports Fiscal First Quarter 2016 Financial Results
Feb 2, 2016
Anavex to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016
Feb 1, 2016
14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy
28
29
30
31
32
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
